Octreotide vs Lanreotide vs Pasireotide: Somatostatin Analogs Compared
Octreotide vs lanreotide vs pasireotide compared by receptor profile, approved uses, acromegaly and NET evidence, route and safety tradeoffs.
Octreotide vs lanreotide vs pasireotide is a common search because the three drugs sit in the same somatostatin family. That family link is real, but it can hide important differences.
All three are synthetic peptide drugs that act through somatostatin receptors. They are used in specialist endocrine or oncology settings, not as general peptide therapy. The right comparison depends on the problem being treated: acromegaly, functional neuroendocrine tumor symptoms, tumor-growth control, Cushing disease or a later-line endocrine situation.
For the single-drug guides, read octreotide, lanreotide and pasireotide. This page compares the class without turning it into dosing advice.
The Short Version
| Drug | Core identity | Main use context | Evidence anchor | Safety issue to watch |
|---|---|---|---|---|
| Octreotide | Long-acting somatostatin analog with injectable and oral products | Acromegaly, carcinoid/VIPoma symptoms, selected NET tumor control | PROMID for metastatic midgut NETs; acromegaly meta-analyses; oral octreotide trials in selected responders | Gallbladder disease, glucose changes, thyroid/cardiac monitoring, GI effects |
| Lanreotide | Long-acting depot somatostatin analog | Acromegaly, GEP-NET tumor control, carcinoid syndrome | CLARINET for metastatic enteropancreatic NETs; label-backed acromegaly and carcinoid syndrome uses | Gallbladder disease, glucose changes, injection-site effects, GI effects |
| Pasireotide | Multi-receptor analog with strong subtype 5 activity | Cushing disease and acromegaly in selected settings | NEJM Cushing disease trial; PAOLA acromegaly trial after inadequate control on older analogs | Hyperglycemia and diabetes risk are central |
The blunt summary: octreotide and lanreotide are the main older workhorses for many acromegaly and neuroendocrine tumor questions. Pasireotide is a different tool with broader receptor binding and a more serious glucose-management issue.
Why Somatostatin Analogs Differ
Native somatostatin is a peptide hormone with a short half-life. It suppresses growth hormone, TSH and several gastrointestinal and pancreatic hormones. That biology is useful, but native somatostatin is too short-lived for many chronic drug uses.
Synthetic analogs were designed to keep useful receptor activity while lasting longer. The details matter:
- Receptor subtype binding changes what a drug can suppress.
- Depot formulation changes the injection schedule and patient workflow.
- Route matters. Oral octreotide exists for selected acromegaly patients, while lanreotide is a deep subcutaneous depot and pasireotide has subcutaneous and long-acting intramuscular products.
- Disease context matters more than class name.
The class is easiest to understand by separating three questions: what receptor profile does the drug have, what label does it carry, and what trial population actually showed benefit?
For more background on peptide drug behavior, see peptide half-life explained and what are peptides.
Octreotide: The Broad Reference Point
Octreotide is often the reference somatostatin analog because it has a long clinical history and several formulations. Sandostatin LAR Depot is the long-acting injectable product. Mycapssa is an oral delayed-release octreotide product for selected adults with acromegaly who responded to and tolerated injectable octreotide or lanreotide.
In acromegaly, meta-analyses support long-acting somatostatin analogs as a biochemical-control strategy, though response varies by tumor biology and prior treatment. Oral octreotide trials answer a narrower question: whether selected patients already controlled on injectable somatostatin receptor ligands can maintain response after switching.
In neuroendocrine tumors, PROMID studied octreotide LAR in metastatic midgut NETs and found longer time to tumor progression compared with placebo. That is not a universal claim for every NET, but it is a meaningful evidence anchor for octreotide in a defined setting.
Octreotide also has a role around peptide receptor radionuclide therapy, because Lutathera trials used long-acting octreotide in the treatment protocol and comparator arms.
Lanreotide: Similar Family, Different Workflow
Lanreotide is another long-acting somatostatin analog, sold in the United States as Somatuline Depot. It is delivered as a deep subcutaneous depot injection. PeptideStat also tracks it as a structured database entry at lanreotide.
Its label includes acromegaly, unresectable or metastatic well or moderately differentiated GEP-NETs to improve progression-free survival, and carcinoid syndrome to reduce the need for short-acting rescue therapy.
The CLARINET trial is the key NET evidence anchor. It studied lanreotide in metastatic enteropancreatic neuroendocrine tumors and found prolonged progression-free survival compared with placebo. Later open-label extension data added longer-term context, but the cleanest core claim remains tied to the original randomized population.
Lanreotide and octreotide overlap enough that comparison is reasonable. They are not interchangeable in every patient. Formulation, injection technique, response, access, symptom pattern and prior treatment all matter.
Pasireotide: Broader Receptors, Bigger Glucose Issue
Pasireotide is still a somatostatin analog, but its receptor profile is not just "stronger octreotide." It binds several somatostatin receptor subtypes, with high affinity for subtype 5. That is why it is discussed for Cushing disease and for acromegaly that is inadequately controlled on older somatostatin analogs.
The NEJM Cushing disease trial showed that pasireotide can reduce urinary free cortisol in a subset of patients, but hyperglycemia was a major issue. In acromegaly, the PAOLA trial compared pasireotide LAR with continued octreotide or lanreotide in patients who were inadequately controlled, and pasireotide LAR showed better biochemical control in that selected context.
That evidence does not make pasireotide the default choice for every somatostatin question. Its glucose effects can be clinically important, and the drug is usually framed as a specialist option rather than a simple replacement for octreotide or lanreotide.
For database context, see pasireotide.
How To Compare Them In Practice
The most useful comparison is not "which one is best?" It is "best matched to which indication and patient context?"
| Comparison point | Octreotide | Lanreotide | Pasireotide |
|---|---|---|---|
| Receptor emphasis | Mainly useful SSTR2/SSTR5 activity | Mainly useful SSTR2/SSTR5 activity | Broader profile, high SSTR5 affinity |
| Common workflow | Short-acting, depot injectable and selected oral maintenance options | Deep subcutaneous depot | Subcutaneous Cushing disease product and long-acting acromegaly product |
| NET evidence | PROMID for midgut NET tumor-growth control | CLARINET for enteropancreatic NET tumor-growth control | Not the usual first NET comparison drug |
| Acromegaly role | Established somatostatin analog option | Established somatostatin analog option | Option in selected inadequately controlled cases |
| Major differentiator | Formulation breadth and long history | Depot workflow and CLARINET evidence | Hyperglycemia risk and broader receptor binding |
This is also why peptide-market language can be misleading. A vial labeled with a peptide name does not recreate the clinical product, depot formulation, labeling, monitoring or trial evidence behind these drugs.
Safety Comparison
Octreotide and lanreotide share several class issues: gastrointestinal effects, gallbladder problems, changes in glucose regulation, possible thyroid effects and heart-rate or conduction considerations in susceptible patients. Product labels also include monitoring details that depend on route and indication.
Pasireotide overlaps with the class but has a more prominent hyperglycemia and diabetes risk. That risk is not a minor footnote. It is central to how the drug is selected and monitored in Cushing disease and acromegaly.
None of these drugs should be reduced to "peptide side effects." They suppress hormonal and gastrointestinal signaling pathways. Those effects can be useful in the right disease, but they are also why monitoring matters.
Claim Checks
| Claim | Better question |
|---|---|
| "Lanreotide is just long-acting octreotide." | What does each product label cover, and what formulation is being used? |
| "Pasireotide is stronger, so it is better." | Better for which receptor profile, disease state and glucose-risk context? |
| "Oral octreotide replaces injections." | Was the patient already controlled on injectable somatostatin receptor ligands and eligible for the oral product label? |
| "Somatostatin analogs are anti-aging peptides." | What approved indication, trial population and monitoring plan supports that claim? |
| "These peptides are interchangeable with research products." | Does the product match a regulated prescription formulation with quality controls and labeling? |
If a source cannot answer those questions, it is probably borrowing medical credibility from the drug class without carrying over the evidence.
Safety Note
Somatostatin analogs are prescription drugs used in endocrine and oncology care. They should not be used as general peptide protocols, and this comparison is not dosing advice. Acromegaly, neuroendocrine tumors and Cushing disease all require specialist diagnosis, lab monitoring and follow-up.
Bottom Line
Octreotide, lanreotide and pasireotide are related peptide drugs, but they are not three versions of the same choice.
Octreotide has the broadest formulation history and strong reference evidence. Lanreotide has a distinct depot workflow and strong CLARINET evidence in enteropancreatic NETs. Pasireotide has broader receptor activity and important evidence in Cushing disease and selected acromegaly settings, balanced by a clear glucose-risk burden.
The best comparison is evidence first: indication, receptor profile, trial population, formulation and safety monitoring.
References
DailyMed. Sandostatin LAR Depot (octreotide acetate) prescribing information. Published December 23, 2025.
DailyMed. Mycapssa (octreotide) prescribing information. Published July 28, 2025.
DailyMed. Somatuline Depot (lanreotide acetate) prescribing information. Published October 17, 2024.
DailyMed. Signifor LAR (pasireotide) prescribing information. Published July 19, 2024.
Freda PU, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2005.
Rinke A, et al. Placebo-controlled study of octreotide LAR in metastatic neuroendocrine midgut tumors: PROMID. Journal of Clinical Oncology, 2009.
Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine, 2014.
Caplin ME, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine, 2021.
Colao A, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine, 2012.
Gadelha MR, et al. Pasireotide versus continued treatment with octreotide or lanreotide in inadequately controlled acromegaly (PAOLA). Lancet Diabetes and Endocrinology, 2014.
Gadelha MR, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly. Lancet Diabetes and Endocrinology, 2022.